Bradley Merrill Thompson
By Bradley Merrill Thompson 05:20 pm December 23, 2020
As the agency's workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green's Bradley Merrill Thompson.
The Daily Brief Newsletter
Get daily news updates from Healthcare IT News.